Articles > Pre Market Movers: Sarepta Stock Surges on Positive Three-Year Study Results for Elevidys
- Sarepta Therapeutics reports positive and statistically significant results in a study evaluating the efficacy of its gene therapy, Elevidys, for Duchenne muscular dystrophy
- Three-year data shows that the gene therapy helps maintain motor function in patients
- The EMBARK study, a global Phase 3 study, demonstrates that Elevidys significantly slows disease progression in ambulatory Duchenne patients
- Sarepta's precision genetic medicine for rare diseases continues to show promising results in clinical trials
- U.S. stock futures dropped on Monday as investors prepare for mega-cap earnings reports
Sarepta Therapeutics has seen a surge in its stock price following the release of positive three-year study results for its gene therapy, Elevidys. The company reported statistically significant data in a study evaluating the efficacy of its blockbuster gene therapy for Duchenne muscular dystrophy. The three-year data shows that Sarepta's gene therapy helps maintain motor function in patients with the progressive muscle-wasting disorder.
The EMBARK study, a global Phase 3 study, revealed that Elevidys showed sustained benefits in patients' ability to control and coordinate movement. The study focused on ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at the time of treatment and at the time of last assessment. The results indicated that Elevidys significantly slows disease progression on key functional measures in these patients.
Sarepta Therapeutics, known for its precision genetic medicine for rare diseases, continues to show promising results in clinical trials. The company's focus on developing innovative therapies for rare and devastating disorders has led to positive outcomes in its gene therapy research. Investors have responded positively to the news, driving up Sarepta's stock price.
In the broader market, U.S. stock futures dropped on Monday following a mixed close on Friday. Investors are bracing for mega-cap earnings reports, with futures of major benchmark indices lower. The stock market remains volatile as investors monitor corporate earnings and economic indicators for signs of growth and stability.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Pre Market Movers: Sarepta Stock Surges on Positive Three-Year Study Results for Elevidys
By KlickAnalytics Data Insights | January 26, 2026 08:58AM ET
Key Points
- Sarepta Therapeutics reports positive and statistically significant results in a study evaluating the efficacy of its gene therapy, Elevidys, for Duchenne muscular dystrophy
- Three-year data shows that the gene therapy helps maintain motor function in patients
- The EMBARK study, a global Phase 3 study, demonstrates that Elevidys significantly slows disease progression in ambulatory Duchenne patients
- Sarepta's precision genetic medicine for rare diseases continues to show promising results in clinical trials
- U.S. stock futures dropped on Monday as investors prepare for mega-cap earnings reports
Sarepta Therapeutics has seen a surge in its stock price following the release of positive three-year study results for its gene therapy, Elevidys. The company reported statistically significant data in a study evaluating the efficacy of its blockbuster gene therapy for Duchenne muscular dystrophy. The three-year data shows that Sarepta's gene therapy helps maintain motor function in patients with the progressive muscle-wasting disorder.
The EMBARK study, a global Phase 3 study, revealed that Elevidys showed sustained benefits in patients' ability to control and coordinate movement. The study focused on ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at the time of treatment and at the time of last assessment. The results indicated that Elevidys significantly slows disease progression on key functional measures in these patients.
Sarepta Therapeutics, known for its precision genetic medicine for rare diseases, continues to show promising results in clinical trials. The company's focus on developing innovative therapies for rare and devastating disorders has led to positive outcomes in its gene therapy research. Investors have responded positively to the news, driving up Sarepta's stock price.
In the broader market, U.S. stock futures dropped on Monday following a mixed close on Friday. Investors are bracing for mega-cap earnings reports, with futures of major benchmark indices lower. The stock market remains volatile as investors monitor corporate earnings and economic indicators for signs of growth and stability.
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.